Teva and Chiesi spend $2.6B on rare disease acquisitions in three-day span

Teva acquired Emalex Biosciences for $700M to gain access to experimental Tourette syndrome treatments. The deal represents Teva's largest acquisition in a decade and targets synergies with its existing neurology business.

Neurology department heads should review current Tourette treatment protocols and supplier relationships. Contact Teva's medical affairs team within 30 days to understand transition timelines for any existing Emalex collaborations.

Chiesi acquired KalVista Pharmaceuticals for $1.9B to secure Ekterly, an oral therapy for hereditary angioedema. The acquisition marks the fifth biotech buyout this week and validates Wall Street interest in oral HAE treatments.

Rare disease program directors should audit current HAE patient populations and treatment costs. Schedule vendor meetings with Chiesi representatives before Q3 to understand Ekterly's formulary positioning and patient access programs.

Pfizer reported statistically significant progression-free survival improvement for Elrexfio in relapsed multiple myeloma patients. The Phase 3 results position the drug for potential label expansion beyond current indications.

Hematology-oncology department heads should review current myeloma treatment protocols and patient populations eligible for Elrexfio. Request detailed Phase 3 data from Pfizer medical affairs within two weeks to assess formulary implications.

Humana's CenterWell Pharmacy selected Mark Cuban Cost Plus Drug Company as a pharmacy partner for employer-based programs. The partnership combines Cost Plus's transparent pricing model with CenterWell's digital pharmacy platform.

Benefits administrators should compare current generic drug costs against Cost Plus pricing for top 50 employer formulary drugs. Request CenterWell partnership details from Humana representatives before next open enrollment period.